Trials / Completed
CompletedNCT01492777
Pharmacogenetics of Acenocoumarol
Stabilization of Anticoagulation by Acenocoumarol: Role of Genetic Vulnerability and Risk of Drug Interactions
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 115 (actual)
- Sponsor
- University Hospital, Geneva · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The use of oral anticoagulation is marked by an elevated risk of adverse drug events (ADE) due to a narrow therapeutic window leading to important medical and economical consequences. The risk of ADE is increased partly by drug interactions and recently identified genetic factors influencing the metabolism of coumarins (polymorphism of the cytochrome P450 CYP2C9) as well as the target enzyme of the coumarins (polymorphism of the vitamin K epoxide reductase complex subunit 1 (VKORC1). The objective is to determine the impact of several genotypes on acenocoumarol treatment and on vulnerability to drug-drug interactions.
Conditions
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2011-03-01
- Completion
- 2012-03-01
- First posted
- 2011-12-15
- Last updated
- 2013-06-21
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT01492777. Inclusion in this directory is not an endorsement.